Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets Column: 30

Similar documents
Tamsulosin Hydrochloride Capsules

Drospirenone and Ethinyl Estradiol Tablets. Type of Posting. Revision Bulletin Posting Date. 31 July 2015 Official Date

Minor editorial changes have been made to update the monograph to the current USP style.

SIMULTANEOUS DETERMINATION OF TELMISARTAN AND HYDROCHLOROTHIAZIDE IN TABLET DOSAGE FORM USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

Analytical Test Report

LUMEFANTRINE Draft proposal for The International Pharmacopoeia (October 2006)

ERDOSTEINE - MONOGRAPH.

SUCRALOSE. White to off-white, practically odourless crystalline powder

Simultaneous determination of aspartame, benzoic acid, caffeine, and saccharin in sugar-free beverages using HPLC

ETHYL LAUROYL ARGINATE

CONFIRMATION OF ZOLPIDEM BY LIQUID CHROMATOGRAPHY MASS SPECTROMETRY

ANALYTICAL METHOD DEVELOPMENT FOR DISSOLUTION RELEASE OF FINISHED SOLID ORAL DOSAGE FORMS

Research Article. Stress study and estimation of a potent anticoagulant drug rivaroxaban by a validated HPLC method: Technology transfer to UPLC

Reversed Phase High Presssure Liquid Chromatograhphic Technique for Determination of Sodium Alginate from Oral Suspension

Articaine & Epinephrine Injection according to USP method

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PARACETAMOL ORAL SUSPENSION (September 2010)

Simultaneous determination of L-ascorbic acid and D-iso-ascorbic acid (erythorbic acid) in wine by HPLC and UV-detection (Resolution Oeno 11/2008)

Transfer of a USP method for prednisolone from normal phase HPLC to SFC using the Agilent 1260 Infinity Hybrid SFC/UHPLC System Saving time and costs

α-cyclodextrin SYNONYMS α-schardinger dextrin, α-dextrin, cyclohexaamylose, cyclomaltohexaose, α- cycloamylase

Analysis of Various Vitamins in Multivitamin Tablets

PEYOTE & MESCALINE Latest Revision: June 27, 2005

Journal of Chemical and Pharmaceutical Research

Preparation of frequently used solutions

TECHNICAL BULLETIN. HIS-Select Nickel Affinity Gel. Catalog Number P6611 Storage Temperature 2 8 C

Automated Method Development Utilizing Software-Based Optimization and Direct Instrument Control

APPLICATIONS MANUAL. Ifosfamide in blood serum Ingredients in blood serum Organophosphorus pesticides in tea leaf... 5

BRIEFING Plastic Packaging Systems for Pharmaceutical Use.

EXPERIMENT 5. Molecular Absorption Spectroscopy: Determination of Iron With 1,10-Phenanthroline

A NEW METHOD DEVELOPMENT AND VALIDATION FOR ANALYSIS OF RIVAROXABAN IN FORMULATION BY RP HPLC

Vitamin C quantification using reversed-phase ion-pairing HPLC

Thermo Scientific Syncronis HPLC Columns. Technical Manual

Standard Operating Procedure for Total Kjeldahl Nitrogen (Lachat Method)

Technical Procedure for the Solid Phase Extraction of Acidic, Neutral and Basic Drugs for GC-MS Analysis

Development of validated RP- HPLC method for estimation of rivaroxaban in pharmaceutical formulation

SODIUM CARBOXYMETHYL CELLULOSE

Develop a Quantitative Analytical Method for low (» 1 ppm) levels of Sulfate

POROS CaptureSelect affinity columns for highspeed quantification of IgG Fc fusion proteins

All the prepared formulations were subjected for following. evaluation parameters and obtained results were showed in Tables 6.3 &

United States Department of Agriculture Food Safety and Inspection Service, Office of Public Health Science

Extraction of Cannabinoids in Marijuana and Edibles by QuEChERS

IN VITRO BINDING BIOEQUIVALENCE STUDY SUMMARY TABLES AND SAS TRANSPORT FORMATTED TABLES FOR DATASET SUBMISSION

ß-CYCLODEXTRIN SYNONYMS

International Journal of Pharma and Bio Sciences V1(2)2010

Esterification Method 1 Method to 2800 mg/l (as acetic acid) Reagent Solution

HPLC Analysis of Acetaminophen Tablets with Waters Alliance and Agilent Supplies

LACHAT METHOD NUMBER D Rev 1, 21 March 2011 SCOPE AND APPLICATION Approximately g CN/L g CN/L. 09e

The basic division explosives for forensic purposes is shown in Fig. 1

[ Care and Use Manual ]

竞 争 性 分 析 Epitope Mapping 实 验 方 法

Application Note. Determination of Nitrite and Nitrate in Fruit Juices by UV Detection. Summary. Introduction. Experimental Sample Preparation

Opiates in Urine by SAMHSA GC/MS

Guide to Reverse Phase SpinColumns Chromatography for Sample Prep

PECTINS. SYNONYMS INS No. 440 DEFINITION DESCRIPTION. FUNCTIONAL USES Gelling agent, thickener, stabilizer, emulsifier CHARACTERISTICS

Transformation Protocol

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE

Development and validation of a dissolution test for Candesartan cilexetil in tablet forms using reverse phase High performance liquid chromatography

Peptide synthesis, radiolabelling and radiochemical analysis

Color, True and Apparent

EUDRAGIT E 100, EUDRAGIT E PO and

United States Department of Agriculture Food Safety and Inspection Service, Office of Public Health Science

BUFFERS and MEDIAS Coomassie Blue Staining Solution Coomassie blue Destaining Solution DMEM Normal Cell Culture Media

Color, True and Apparent

High Performance Thin Layer Chromatographic Method for Estimation of Cefprozil in Tablet Dosage Form

FATAL INTOXICATION BY CIBENZOLINE (CIPRALAN )

Materials for Pharmaceutical Manufacturing

RPCI 004 v.002 Staining Procedure For all Directly Conjugated Reagents (Whole Blood Method)

USP Certificate PREDNISONE TABLETS. USP Catalog No.: USP Lot No.: R031Y0 (10 mg nominal prednisone content per tablet)

Analysis of Casein and Whey Protein in Whole, 2%, and Skim Milk by Capillary Gel Electrophoresis

POROS CaptureSelect affinity columns for rapid, small-scale purification and sample preparation of recombinant proteins

Oasis HLB Cartridges and 96-Well Plates

An In-Gel Digestion Protocol

Standard Analytical Methods of Bioactive Metabolitesfrom Lonicera japonica Flower Buds by HPLC-DAD and HPLC-MS/MS

PVV Satyanaryana et al., IJSID, 2012, 2 (1), International Journal of Science Innovations and Discoveries

Purification of reaction mixtures using flash chromatography.

Generic drugs are copies of innovator drug products

Determination of Anabolic Steroids in Horse Urine by SPE and LC-MS/MS

Carolina s Solution Preparation Manual

Journal of Chemical and Pharmaceutical Research, 2012, 4(6): Research Article

Determine Osmolarity Activity Using RFP under PompC

Protocol: HPLC (amino acids)

Determining the Quantity of Iron in a Vitamin Tablet. Evaluation copy

Determination of calcium by Standardized EDTA Solution

TANNIC ACID. SYNONYMS Tannins (food grade), gallotannic acid, INS No. 181 DEFINITION DESCRIPTION

High performance thin layer chromatographic method for estimation of deflazacort in tablet

Journal of Chemical and Pharmaceutical Research

Monoclonal Antibody Fragment Separation and Characterization Using Size Exclusion Chromatography Coupled with Mass Spectrometry

RECONSTITUTING MEDICATIONS: HOW TO FLUFF UP MEDICATIONS

Determination of Caffeine in Beverages HPLC-1

Validation and Calibration of Analytical Instruments a D.Gowrisankar, b K.Abbulu, c O.Bala Souri, K.Sujana*

Supplementary Materials and Methods (Metabolomics analysis)

OREGON GRAPE FOR HOMOEOPATHIC PREPARATIONS BERBERIS AQUIFOLIUM FOR HOMOEOPATHIC PREPARATIONS

Determination of caffeine and vitamin B6 in energy drinks by high-performance liquid chromatography (HPLC)

Method Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

105 Adopted:

ISOLATION OF CAFFEINE FROM TEA

Phosphorus, colorimetry, phosphomolybdate, automated-segmented flow

ANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS

HEXANES. Insoluble in water, soluble in ether, alcohol, and acetone. Neutral to methyl orange (ph indicator) Not more than 0.

Transcription:

. Mode: Revision Bulletin Official April 1, 2013 Cetirizine 1 Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets Column: 30 LC Detector: UV 230 nm Column: 4.6-mm 15-cm; 3.5-µm packing L1 Temperatures Autosampler: 5 DEFINITION Flow rate: 1mL/min Cetirizine Hydrochloride and Pseudoephedrine Hydrochlo- ride Extended-Release Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of cetirizine hydro- Sample: Standard chloride (C 21H 25ClN 2O 3 2HCl) and pseudoephedrine hy- drochloride (C 10H 15NO HCl). Column efficiency: NLT 3000 theoretical plates Tailing factor: NMT 1.5 IDENTIFICATION Relative standard deviation: NMT 2.0% A. The retention times of the major peaks of the Sample correspond to those of the Standard, as obtained in the Assay. Samples: Standard and Sample Calculate the percentage of cetirizine hydrochloride (C 21H 25ClN 2O 3 2HCl) in the portion of Tablets taken: ASSAY CETIRIZINE HYDROCHLORIDE Result = (r U/r S) (C S/C U) 100 Buffer: 3.5 g/l of monobasic ammonium phosphate and 1.0 g/l of tetrabutylammonium bisulfate in water. r U = peak response of cetirizine from the Sample Adjust with phosphoric acid to a ph of 2.5. Diluent: Methanol and Buffer (2:3) r S = peak response of cetirizine from the Standard Solution A: Acetonitrile, methanol, and Buffer (9:2:29) Solution B: Acetonitrile C S = concentration of USP Cetirizine Hydrochloride Mobile phase: See Table 1. RS in the Standard C U = nominal concentration of cetirizine Table 1 hydrochloride in the Sample Time Solution A Solution B Acceptance criteria: 90.0% 110.0% (min) (%) (%) PSEUDOEPHEDRINE HYDROCHLORIDE 0 100 0 Buffer: 0.8 g/l of ammonium acetate in water. To 1 L 27.0 100 0 of the add 1.0 ml of triethylamine. Adjust 30.0 0 100 30.1 100 0 35.0 100 0 Standard stock : 0.5 mg/ml of USP Cetirizine Hydrochloride RS in Diluent. [NOTE Sonicate to dissolve.] Standard : 0.025 mg/ml of USP Cetirizine Hy- drochloride RS in Diluent from the Standard stock Sample : 0.025 mg/ml of cetirizine hydrochlo- ride (from NMT 10 finely powdered Tablets) prepared as follows. Dissolve the Tablets first in methanol, using 22.5% of the final flask volume. Sonicate for NLT 20 min with vigorous swirling every 5 min. To the add a volume of Buffer equal to 26% of the final flask volume. Allow the to equilibrate to room tem- perature. Dilute with Diluent to volume. Pass a portion through a membrane filter of 0.45-µm pore size. with glacial acetic acid to a ph of 4.5. Mobile phase: Acetonitrile and Buffer (3:7) Standard : 0.5 mg/ml of USP Pseudoephedrine Hydrochloride RS in Mobile phase. [NOTE Sonicate to dissolve.] Sample stock : 2.4 mg/ml of pseudoephedrine hydrochloride (from 5 finely powdered Tablets) prepared as follows. Dissolve the crushed Tablets first in acetonitrile, using 24% of the final flask volume. Sonicate for NLT 15 min. To the add a volume of Buffer equal to 56% of the final flask volume. Sonicate for NLT 15 min. Shake the flask for NLT 10 min. Allow the to equilibrate to room temperature. Dilute with Mobile phase to volume. Centrifuge a portion for 15 min to obtain a clear supernatant. Sample : 0.5 mg/ml of pseudoephedrine hy- drochloride in Mobile phase from the Sample stock. Pass the through a membrane filter of 0.45-µm pore size. Detector: UV 254 nm Column: 4.6-mm 15-cm; 5-µm packing L9 Flow rate: 1.5 ml/min Run time: 2 times the retention time of pseudoephedrine

2 Cetirizine Official April 1, 2013 Calculate the percentage of cetirizine hydrochloride Sample: Standard dissolved: Column efficiency: NLT 1000 theoretical plates Result = (r U/r S) (C S/L) V 100 Tailing factor: NMT 2.0 Relative standard deviation: NMT 2.0% r U = peak response of cetirizine from the Sample Samples: Standard and Sample r S = peak response of cetirizine from the Standard Calculate the percentage of pseudoephedrine hydro- chloride (C 10H 15NO HCl) in the portion of Tablets C S = concentration of cetirizine hydrochloride in taken: the Standard L = label claim for cetirizine hydrochloride Result = (r U/r S) (C S/C U) 100 V = volume of Medium, 500 ml r U = peak response of pseudoephedrine from the Calculate the percentage of pseudoephedrine Sample hydrochloride dissolved at each time point: r S = peak response of pseudoephedrine from the Standard Q 30 = (r U/r S) (C S/L) V 100 Hydrochloride RS in the Standard Q 1 = (Q 30 5/500) + [(r U/r S) (C S/L) 495 100] C U = nominal concentration of pseudoephedrine hydrochloride in the Sample Q 2 = (Q 30 5/500) + (Q 1 5/495) + [(r U/r S) (C S/L) 490 100] Acceptance criteria: 90.0% 110.0% PERFORMANCE TESTS Q 6 = (Q 30 5/500) + (Q 1 5/495) + (Q 2 5/490) + [(r U/r S) (C S/L) 485 100] Change to read: r U = peak response of pseudoephedrine from the DISSOLUTION 711 Sample.Test r S = peak response of pseudoephedrine from the 1 (RB 1-Apr-2013) Medium: 0.1 N hydrochloric acid; 500 ml, deaerated Standard Apparatus 1: 100 rpm C S = concentration of pseudoephedrine Time: 30 min for cetirizine hydrochloride and 30 min hydrochloride in the Standard (used only for adjustments in the calculations); 1, 2, and 6 h for pseudoephedrine hydrochloride L = label claim for pseudoephedrine hydrochloride Buffer: 0.77 g/l of ammonium acetate in water. To 1 L of the add 1.0 ml of triethylamine. Adjust V = initial volume of Medium, 500 ml with glacial acetic acid to a ph of 4.5 ± 0.05..Tolerances Mobile phase: Acetonitrile and Buffer (3:7) Cetirizine hydrochloride: NLT 80% (Q) of the la- Standard stock : 0.5 mg/ml of USP Cein 30 min beled amount of cetirizine hydrochloride is dissolved tirizine Hydrochloride RS in water Standard : 0.24 mg/ml of USP Pseudoe- Pseudoephedrine hydrochloride (C 10H 15NO HCl): phedrine Hydrochloride RS and 0.01 mg/ml of USP See Table 2. Cetirizine Hydrochloride RS in Medium from the Standard stock Table 2 Sample : At the times specified, withdraw Time Amount 5 ml of the under test, and pass through a (h) Dissolved suitable filter of 0.45-µm pore size, discarding the first few ml. 1 30% 50% 2 50% 70% 6 NLT 80% Detector: UV, 230 nm for cetirizine hydrochloride, The percentages of the labeled amount of pseudoe- 254 nm for pseudoephedrine hydrochloride phedrine hydrochloride dissolved at the times speci- Column: 4.6-mm 15-cm; 5-µm packing L9 fied conform to Acceptance Table 2 in 711. Flow rate: 1.5 ml/min Test 2: If the product complies with this test, the label- ing indicates that it meets USP Dis Test 2. Run time: 2 times the retention time of Medium: 0.1 N HCl; 500 ml pseudoephedrine Apparatus 1: 100 rpm Time: 30 min for cetirizine hydrochloride and 30 min- Sample: Standard utes (used only for adjustments in the calculations); 1, 2, 4 and 8 h for pseudoephedrine hydrochloride Tailing factor: NMT 2.0 for both cetirizine and Buffer: 6.8 g/l of sodium acetate and 16.2 g/l of sopseudoephedrine dium 1-octanesulfonate Relative standard deviation: NMT 2.0% for both Mobile phase: Methanol and Buffer (50:50). Adjust cetirizine and pseudoephedrine with glacial acetic acid to a ph of 5.5. Standard : 0.01 mg/ml of USP Cetirizine Hydrochloride RS and 0.24 mg/ml of USP Pseudoephedrine Hydrochloride RS in Medium

Official April 1, 2013 Cetirizine 3 Sample : Pass a 5-mL portion of the C i = concentration of pseudoephedrine under test through a suitable filter of 0.45-µm pore hydrochloride in the portion of sample size. withdrawn at time point (i) V = volume of the Medium (500 ml) V S = volume of the Sample withdrawn from the Medium (ml) Detector: UV 242 nm L = label claim for pseudoephedrine hydrochloride Column: 4.6-mm 10-cm; 5-µm packing L1 Column temperature: 35 Tolerances Flow rate: 2 ml/min Cetirizine hydrochloride: NLT 75% (Q) of the la- Injection volume: 100 µl beled amount of cetirizine hydrochloride (C 21H 25ClN 2O 3 2HCl) is dissolved. [NOTE The relative retention times for pseudoephed- Pseudoephedrine hydrochloride (C 10H 15NO HCl): rine and cetirizine are 1.0 and 2.9, respectively.] See Table 3. Sample: Standard Table 3 Column efficiency: NLT 2000 theoretical plates for both pseudoephedrine and cetirizine Time point Time Amount Tailing factor: NMT 2.0 for both pseudoephedrine (i) (h) Dissolved and cetirizine 1 0.5 Relative standard deviation: NMT 2.0% for both 2 1 30% 50% pseudoephedrine and cetirizine 3 2 50% 70% 4 4 70% 90% Samples: Standard and Sample Calculate the percentage of the labeled amount of cetirizine 5 8 NLT 80% hydrochloride (C 21H 25ClN 2O 3 2HCl) dissolved: The percentages of the labeled amount of pseudoephedrine hydrochloride dissolved at the times speci- U/r S) (C S/L) V 100 Result = (r fied conform to Acceptance Table 2 in 711. (RB 1-Aprr 2013) U = peak response of cetirizine from the Sample UNIFORMITY OF DOSAGE UNITS 905 : Meet the r S = peak response of cetirizine from the Standard requirements IMPURITIES C S = concentration of USP Cetirizine Hydrochloride CETIRIZINE HYDROCHLORIDE RELATED COMPOUNDS RS in the Standard Buffer, Diluent, Solution A, and Solution B: Proceed L = label claim as directed in the Assay for Cetirizine hydrochloride. V = volume of Medium, 500 ml Mobile phase: See Table 4. Calculate the concentration (C i) of pseudoephedrine hydrochloride (C 10H 15NO HCl) in the sample withdrawn from the vessel at each time point (i) Table 4 shown in Table 3: Time Solution A Solution B Result i = (r U/r S) C S (min) (%) (%) 0 100 0 r U = peak response of pseudoephedrine from the 27 100 0 Sample 45 60 40 r S = peak response of pseudoephedrine from the 65 60 40 Standard 65.1 100 0 75 100 0 Hydrochloride RS in the Standard Standard stock : 0.5 mg/ml of USP Cetirizine Calculate the percentage of the labeled amounts (Q i) Hydrochloride RS in Diluent. [NOTE Sonicate to of pseudoephedrine hydrochloride (C 10H 15NO HCl) dissolve.] dissolved at each time point (i) shown in Table 3: Standard : 1 µg/ml of USP Cetirizine Hydrochloride Result 1 = C 1 V (1/L) 100 RS in Diluent from the Standard stock Sample stock : 0.5 mg/ml of cetirizine hydrochloride (from NMT 10 finely powdered Tablets) prepared Result 2 = {[C 2 (V V s)] + (C 1 V s)} (1/L) 100 as follows. Dissolve the Tablets first in methanol, using 70% of the final flask volume. Sonicate for 15 min, and then shake for 15 min. Allow the to Result 3 = {[C 3 [V (2 V S)]] + [(C 2 + C 1) V S]} (1/L) cool to room temperature, and dilute with methanol to 100 volume. Centrifuge a portion for 10 min. Sample : 0.2 mg/ml of cetirizine hydrochloride in Buffer from the Sample stock. Pass a por- Result 4 = {[C 4 [V (3 V S)]] + [(C 3 + C 2 + C 1) V S]} (1/L) 100 tion through a suitable membrane filter of 0.45-µm pore size. Result 5 = {[C 5 [V (4 V S)]] + [(C 4 + C 3 + C 2 + C 1) V S]} (1/L) 100

4 Cetirizine Official April 1, 2013 Standard stock : 0.48 mg/ml of USP Pseudoe- Detector: UV 230 nm phedrine Hydrochloride RS in Diluent Column: 4.6-mm 15-cm; 3.5-µm packing L1 Standard : 4.8 µg/ml of USP Pseudoephedrine Temperatures Hydrochloride RS in Diluent from the Standard stock Column: 30 Autosampler: 5 stock : 49 µg/ml of ephe- Flow rate: 1 ml/min drine in Diluent from USP Ephedrine Sulfate RS : 1.96 µg/ml of ephedrine and 0.46 mg/ml of USP Pseudoephedrine Hydrochlo- Sample: Standard ride RS in Standard stock from the System suita- bility stock and the Standard stock, Column efficiency: NLT 1300 theoretical plates respectively Tailing factor: NMT 2.0 Sample stock : 2.4 mg/ml of pseudoephed- Relative standard deviation: NMT 5.0% rine hydrochloride (from NMT 25 finely powdered Tab- lets) prepared as follows. Dissolve the Tablets first in Samples: Standard and Sample methanol, using 75% of the final flask volume. Soni- Calculate the percentage of each impurity in the por- cate for NLT 15 min, and then shake for 15 min. Allow tion of Tablets taken: the to cool to room temperature, and dilute with methanol to volume. Centrifuge a portion for 10 Result = (r U/r S) (C S/C U) (1/F) 100 min. Sample : 0.48 mg/ml of pseudoephedrine hyr U = peak response of the individual impurity from drochloride in Diluent from the Sample stock. the Sample Pass a portion through a suitable membrane filter of r S = peak response of cetirizine from the Standard 0.45-µm pore size. C S = concentration of USP Cetirizine Hydrochloride RS in the Standard C U = nominal concentration of cetirizine Detector: UV 212 nm hydrochloride in the Sample Column: 4.6-mm 25-cm; 4-µm packing L11 Column temperature: 40 F = relative response factor (see Table 5) Flow rate: 1 ml/min Acceptance criteria: See Table 5. Injection volume: 30 µl [NOTE Disregard any peak less than 0.05% of the main peak.] Samples: Standard and Table 5 Re: NLT 1.3 between ephedrine and pseu- Relative Relative Acceptance doephedrine, Retention Response Criteria, Tailing factor: NMT 1.5, Standard Name Time Factor NMT (%) Relative standard deviation: NMT 3.0%, Standard Cetirizineethanol 0.54 1.4 0.3 a. Chlorobenzhydryl piperazine (CBHP) b. 0.57 1.5 0.3 Samples: Standard and Sample Cetirizine 1.0 Calculate the percentage of each impurity in the por- Cetirizine acetic acid 1.30 1.1 0.3 tion of Tablets taken: Cetirizine N-Oxide 1.47 1.2 0.3 Result = (r d. U/r S) (C S/C U) (1/F) 100 Any unspecified deg- radation product 1.0 0.2 r U = peak response of the individual impurity from Total impurities 0.8 the Sample r a. 2-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethanol. S = peak response of pseudoephedrine from the 1-[(4-Chlorophenyl)phenylmethyl]piperazine. Standard b. c. 2-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]acetic acid. 2-[4-[(4-Chlorophenyl)phenylmethyl]-1-oxide-1-piperazinyl]ethoxy]acetic Hydrochloride RS in the Standard d. acid. C U = nominal concentration of pseudoephedrine PSEUDOEPHEDRINE HYDROCHLORIDE RELATED COMPOUNDS Buffer: 11.2 g/l of sodium perchlorate monohydrate in hydrochloride in the Sample water. Adjust with hydrochloric acid to a ph of 2.7. Solution A: Methanol and Buffer (3:17) F = relative response factor (see Table 7) Solution B: Methanol and Buffer (1:1) Acceptance criteria: See Table 7. Diluent: Solution A [NOTE Disregard any peak less than 0.05% of the Mobile phase: See Table 6. main peak.] Table 6 Time Solution A Solution B (min) (%) (%) 0 100 0 10 100 0 35 28 72

Official April 1, 2013 Cetirizine 5.. Table 7 ADDITIONAL REQUIREMENTS PACKAGING AND STORAGE: Preserve in well-closed con- Relative Relative Acceptance tainers. Store at controlled room temperature. Retention Response Criteria, Name Time Factor NMT (%) Ephedrine, b a. 0.95 Add the following: Pseudoephedrine 1.0 Methcathinone 1.1 1.1 0.2. LABELING: When more than one Dis test is given, the labeling states the Dis test used only if c. Any unspecified deg- Test 1 is not used. (RB 1-Apr-2013) radation product 1.0 0.2 USP REFERENCE STANDARDS 11 Total pseudoephed- USP Cetirizine Hydrochloride RS rine related impuri- USP Ephedrine Sulfate RS ties 0.5 USP Pseudoephedrine Hydrochloride RS a. [R-(R*,S*)]-α-[1-(Methylamino)ethyl]-benzenemethanol. b. For system suitability and identification purposes only. c. 2-Methylamino-1-phenylpropan-1-one. Sum of cetirizine and pseudoephedrine related impurities: NMT 1.0%